153 related articles for article (PubMed ID: 38175449)
21. Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients.
Del Castillo A; Gomez-Modet S; Mata JM; Tejedor L
Eur J Surg Oncol; 2023 Jul; 49(7):1184-1188. PubMed ID: 36958951
[TBL] [Abstract][Full Text] [Related]
22. Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers.
Laws A; Dillon K; Kelly BN; Kantor O; Hughes KS; Gadd MA; Smith BL; Lamb LR; Specht M
Ann Surg Oncol; 2020 Nov; 27(12):4819-4827. PubMed ID: 32740737
[TBL] [Abstract][Full Text] [Related]
23. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
[TBL] [Abstract][Full Text] [Related]
24. Targeted Axillary Dissection with
Munck F; Andersen IS; Vejborg I; Gerlach MK; Lanng C; Kroman NT; Tvedskov THF
Ann Surg Oncol; 2023 Jul; 30(7):4135-4142. PubMed ID: 37062781
[TBL] [Abstract][Full Text] [Related]
25. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
[TBL] [Abstract][Full Text] [Related]
26. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
[TBL] [Abstract][Full Text] [Related]
27. New horizons in imaging and surgical assessment of breast cancer lymph node metastasis.
Arjmandi F; Mootz A; Farr D; Reddy S; Dogan B
Breast Cancer Res Treat; 2021 Jun; 187(2):311-322. PubMed ID: 33982209
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study.
Martínez M; Jiménez S; Guzmán F; Fernández M; Arizaga E; Sanz C
Breast J; 2022; 2022():6111907. PubMed ID: 35855102
[TBL] [Abstract][Full Text] [Related]
29. Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.
Banys-Paluchowski M; Gruber IV; Hartkopf A; Paluchowski P; Krawczyk N; Marx M; Brucker S; Hahn M
Arch Gynecol Obstet; 2020 Feb; 301(2):341-353. PubMed ID: 31897672
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization.
Sun J; Henry DA; Carr MJ; Yazdankhahkenary A; Laronga C; Lee MC; Hoover SJ; Sun W; Czerniecki BJ; Khakpour N; Kiluk JV
Clin Breast Cancer; 2021 Jun; 21(3):e189-e193. PubMed ID: 32893094
[TBL] [Abstract][Full Text] [Related]
31. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
32. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.
Di Micco R; Zuber V; Fiacco E; Carriero F; Gattuso MI; Nazzaro L; Panizza P; Gianolli L; Canevari C; Di Muzio N; Pasetti M; Sassi I; Zambetti M; Gentilini OD
Eur J Surg Oncol; 2019 Jun; 45(6):969-975. PubMed ID: 30744944
[TBL] [Abstract][Full Text] [Related]
33. Triple mapping for axillary staging after neoadjuvant therapy: Axillary reverse mapping with indocyanine green and dual agent sentinel lymph node biopsy.
Tasdoven I; Balbaloglu H; Erdemir RU; Bahadir B; Guldeniz Karadeniz C
Medicine (Baltimore); 2022 Dec; 101(52):e32545. PubMed ID: 36596061
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
35. Comparing Methods for Targeted Axillary Dissection in Breast Cancer Patients: A Nationwide, Retrospective Study.
Munck F; Jepsen P; Zeuthen P; Carstensen L; Hauerslev K; Paaskesen CK; Andersen IS; Høyer U; Lanng C; Gerlach MK; Vejborg I; Kroman NT; Tvedskov THF
Ann Surg Oncol; 2023 Oct; 30(11):6361-6369. PubMed ID: 37400618
[TBL] [Abstract][Full Text] [Related]
36. Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients.
Acea-Nebril B; García-Novoa A; Bouzón Alejandro A; Díaz Carballada C; Conde Iglesias C
Breast; 2023 Dec; 72():103592. PubMed ID: 37857128
[TBL] [Abstract][Full Text] [Related]
37. Prospective Evaluation of Radar-Localized Reflector-Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy.
Gallagher KK; Iles K; Kuzmiak C; Louie R; McGuire KP; Ollila DW
J Am Coll Surg; 2022 Apr; 234(4):538-545. PubMed ID: 35290273
[TBL] [Abstract][Full Text] [Related]
38. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
Kuemmel S; Heil J; Rueland A; Seiberling C; Harrach H; Schindowski D; Lubitz J; Hellerhoff K; Ankel C; Graßhoff ST; Deuschle P; Hanf V; Belke K; Dall P; Dorn J; Kaltenecker G; Kuehn T; Beckmann U; Potenberg J; Blohmer JU; Kostara A; Breit E; Holtschmidt J; Traut E; Reinisch M
Ann Surg; 2022 Nov; 276(5):e553-e562. PubMed ID: 33156057
[TBL] [Abstract][Full Text] [Related]
39. Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer.
Liu Y; Wang Y; Feng S; Xu Z; Yao M; Huang X; Li P; Wu L; Liu C; Chen X; Liang C; Liu Z
Breast Cancer Res Treat; 2023 Feb; 197(3):515-523. PubMed ID: 36513955
[TBL] [Abstract][Full Text] [Related]
40. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
